- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03477994
Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing CABG
Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing Coronary Artery Bypass Grafting
This prospective, randomised, double blinded, controlled clinical trial will be conducted in 147 patients between 60 yr and 70 yr , ASA physical status II and III, undergoing CABG. Patients will be randomly allocated to either dexmedetomidine or clonidine (control) groups .Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4
Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur. In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h.Primary end point of the study is the incidence of delirium.The secondary endpoints will be the the duration of extubation, the length of ICU stay, need for inotropic support or vasopressors, hospital stay , mean arterial blood pressure and heart rate , hospital mortality rate , all additional sedatives including overall doses of morphine and haloperidol the incidence of adverse events as bradycardia
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
After Ethics committee approval, and a written informed consent will be taken from every patient, . Patients with a history of mental illness, severe dementia, delirium or undergoing emergency procedures will be excluded.
Anesthesia management will be standardized to minimize any effect of anesthetic type on neurological outcomes. Premedication with midazolam will be limited to a maximum of 0.05 mg/kg.
Anesthesia will be induced with 12 μg/kg fentanyl, 5-7mg/kg thiopental sodium, and 0.15 mg/kg pancuronium and maintained with 1% to 2.0% isoflurane. The heart rate and blood pressure will be maintained within 20% of the baseline values. Anticoagulation will be achieved with heparin to maintain an activated clotting time above 480 s.The CPB circuit will be primed with 1.8 l lactated Ringer's solution and 50 ml of 20% mannitol. Management of CPB will include systemic temperature drift to 32 C, targeted mean perfusion pressure between 60 and 80 mmHg, and pump flow rates of 2.2 l/min/m2 . Myocardial protection will be achieved with antegrade cold blood cardioplegia. A 32-μ m filter (Avecor Affinity, USA)will be used in the arterial perfusion line. Before separation from CPB, patients will be rewarmed to 36 to 37C. After separation from CPB, heparin will be neutralized with protamine sulfate, 1 mg/100 U heparin, to reach an activated clotting time within 10% of baseline.All patients will be transferred to ICU after surgery. Patients will be randomly allocated to either dexmedetomidine or clonidine (control) groups according to a computer-generated randomization code, with allocation ratio 1:1 .Opaque sealed envelopes will be done according to the randomization schedule and opened by a physician not involved in the study . Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4
+4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable A four millilitres vial of dexmedetomidine ( 100 micrograms per ml)will be drawn up and diluted in 46 ml of normal saline.The infusion of dexmedetomidine will be continued for a maximum period of 24 h. Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.Dexmedetomidine infusion will not be discontinued before extubation. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur. In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h.
Five ampoules of clonidine(750 μg) was drawn up and diluted in 45ml of normal saline.
Opioids were titrated to reach pain score 3 out of 10. Pain will be assessed using a standard 10-cm visual analog scale (0, no pain; 10, worst and unbearable pain). Patients received 2 mg morphine as rescue analgesic.
Primary end point of the study is the incidence of delirium, which is defined as a disturbed level of consciousness that develops over a period of hours or days and fluctuates over time.
Delirium will be assessed preoperatively (baseline)and postoperatively, in ICU every 2 hours using the confusion assessment method (CAM) for ICU.(7) When patients are discharged from ICU to the ward, delirium will be assessed using CAM every 8 hours for the next 5 days. The CAM-ICU is used for both ventilated and extubated patients. It included a fourstep algorithm : (1) an acute onset of changes or fluctuations in the course of mental status, (2)inattention, (3) disorganized thinking, and (4) an altered level of consciousness. Patients are delirious if both (1) and (2) were found inanition to either feature (3)or (4). Patients are stated either CAM positive (delirium present) or CAM negative (delirium absent). Incidence of delirium was confirmed by the psychiatry consultant. The onset and duration of delirium will be also recorded. The CAM-ICU and CAM testers were involved in the study . IV haloperidol(2.5-5 mg PRN), will be used as a first-line treatment in delirious patients, a regular dose 1 mg ads until symptoms resolve.
The secondary endpoints will be the the duration of extubation, the length of ICU stay, need for inotropic support or vasopressors, hospital stay , mean arterial blood pressure and heart rate , hospital mortality rate , all additional sedatives including overall doses of morphine and haloperidol, finally the incidence of adverse events as bradycardia, heart block , the need for pacemaker , nausea and vomiting will be recorded as well.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Cairo, Egypten, 11566
- Ain Shams University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
60-70 yrs age ASA II, III Scheduled for CABG -
Exclusion Criteria:
History of mental illness Delirium or dementia patient refusal to participate Emergency procedures Any contraindications to study drugs
-
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: dexmedetomidine group
Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 +4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur. |
an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
Andra namn:
|
Sham Comparator: clonidine group
In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2
μg/kg/h if Richmond assessment sedation score from +1 to +4 Five ampoules of clonidine(750 μg) will be drawn up and diluted in 45ml of normal saline.
|
an infusion of 0.5μg/kg then 0.1-0.2
μg/kg/h if Richmond assessment sedation score from +1 to +4.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
the incidence of delirium
Tidsram: every 4 hours in first day in ICU then every 8h for the next day, after discharge from ICU to the ward it will be checked every 8h for 5 days
|
disturbed level of consciousness that develops over a period of hours or days and fluctuates over time.
|
every 4 hours in first day in ICU then every 8h for the next day, after discharge from ICU to the ward it will be checked every 8h for 5 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
length of ICU stay
Tidsram: 2 days
|
time to stay in ICU discharge to the ward
|
2 days
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Ayman Shoeb, professor, Ain Shams University
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Patologiska processer
- Sjukdomar i nervsystemet
- Postoperativa komplikationer
- Neurologiska manifestationer
- Förvirring
- Neurobehavioral manifestationer
- Neurokognitiva störningar
- Delirium
- Emergence Delirium
- Läkemedels fysiologiska effekter
- Adrenerga medel
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Antihypertensiva medel
- Depressiva medel i centrala nervsystemet
- Autonoma agenter
- Agenter från det perifera nervsystemet
- Analgetika
- Sensoriska systemagenter
- Analgetika, icke-narkotiska
- Adrenerga alfa-2-receptoragonister
- Adrenerga alfa-agonister
- Adrenerga agonister
- Hypnotika och lugnande medel
- Sympatolytika
- Dexmedetomidin
- Klonidin
Andra studie-ID-nummer
- FMASU R 16
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Tidsram för IPD-delning
Kriterier för IPD Sharing Access
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Delirium vid uppkomst
-
DePuy OrthopaedicsAvslutadTotal höftprotesplastik | Pinnacle Metal-on-Metal | Reviderad Pinnacle Metal-on-Metal | Skadlig lokal vävnadsreaktion | MetalljonerFörenta staterna
-
Taipei City HospitalAvslutadPRU (Platelet Reactivity Unit) | APT (Antiplatelet Therapy) | HOTPR (High on Treat Platelet Reactivity)Taiwan
-
University of UtahNational Cancer Institute (NCI)RekryteringTrötthet | Stillasittande livsstil | Metastaserande prostatakarcinom | Steg IV prostatacancer AJCC (American Joint Committee on Cancer) v8 | Steg IVA prostatacancer AJCC (American Joint Committee on Cancer) v8 | Steg IVB Prostatacancer AJCC (American Joint Committee on Cancer) v8Förenta staterna
-
Shaare Zedek Medical CenterOkändCalmmax Cream on UP hos CKD-patienter.Israel
-
Efficacy Care R&D LtdHadassah Medical OrganizationOkändDelirium | Delirium, orsak okänd | Delirium av blandat ursprung | Delirium Förvirringstillstånd | Läkemedelsinducerad deliriumIsrael
-
Johns Hopkins UniversityNational Institute on Aging (NIA)Aktiv, inte rekryterandeDelirium | Delirium vid uppkomst | Hörselnedsättning | Hörselnedsättning, högfrekvent | Hörselnedsättning, sensorineural | Delirium, orsak okänd | Hörselnedsättning, bilateral | Hörselnedsättning | Delirium i ålderdom | Delirium av blandat ursprung | Delirium överlagrat på demens | Delirium Förvirringstillstånd | Delirium... och andra villkorFörenta staterna
-
Oslo University HospitalUniversity of Melbourne; Norwegian Academy of MusicAvslutadDelirium i ålderdom | Delirium av blandat ursprung | Delirium överlagrat på demens | Delirium FörvirringstillståndNorge
-
Universidad de SantanderOkändDelirium av blandat ursprung | Hypoaktivt delirium | Hyperaktivt deliriumColombia
-
Imperial College Healthcare NHS TrustRekryteringHjärtkirurgi | Intensivvårdsavdelning Delirium | Postoperativt deliriumStorbritannien
-
Chinese PLA General HospitalBeijing Tiantan HospitalRekrytering
Kliniska prövningar på Dexmedetomidine
-
Cairo UniversityOkändSpinalbedövningslängdEgypten
-
Guangzhou Women and Children's Medical CenterAvslutadAmbulatoriska kirurgiska ingreppKina
-
Seoul National University Bundang HospitalAvslutad
-
Guangzhou General Hospital of Guangzhou Military...OkändKombinerad spinal-epidural anestesiKina
-
Guangzhou General Hospital of Guangzhou Military...Avslutad
-
Guangzhou General Hospital of Guangzhou Military...AvslutadFarmakodynamisk interaktionKina
-
National Cancer Institute, EgyptAvslutad
-
University Hospital DubravaRekryteringAortaklaffstenos | Systemiskt inflammatoriskt svarKroatien
-
Guangzhou General Hospital of Guangzhou Military...Okänd
-
Children's Hospital Medical Center, CincinnatiAvslutadHjärtsjukdomFörenta staterna